475 related articles for article (PubMed ID: 29046141)
1. Generation and Characterization of a Bispecific Antibody Targeting Both PD-1 and c-MET.
Wu Y; Yu M; Sun Z; Hou W; Wang Y; Yuan Q; Mo W
Protein Pept Lett; 2018 Feb; 24(12):1105-1112. PubMed ID: 29046141
[TBL] [Abstract][Full Text] [Related]
2. A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.
Sun ZJ; Wu Y; Hou WH; Wang YX; Yuan QY; Wang HJ; Yu M
Oncotarget; 2017 Apr; 8(17):29067-29079. PubMed ID: 28404966
[TBL] [Abstract][Full Text] [Related]
3. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
[TBL] [Abstract][Full Text] [Related]
4. A novel bispecific c-MET/CTLA-4 antibody targetting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer.
Li JF; Niu YY; Xing YL; Liu F
Biosci Rep; 2019 May; 39(5):. PubMed ID: 29187584
[TBL] [Abstract][Full Text] [Related]
5. A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy.
Chen YL; Cui Y; Liu X; Liu G; Dong X; Tang L; Hung Y; Wang C; Feng MQ
J Biol Chem; 2021 Dec; 297(6):101420. PubMed ID: 34798072
[TBL] [Abstract][Full Text] [Related]
6. Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy.
Zhang H; Wang Q; Yalavarthi S; Pekar L; Shamnoski S; Hu L; Helming L; Zielonka S; Xu C
Cancer Treat Res Commun; 2024; 39():100805. PubMed ID: 38492435
[TBL] [Abstract][Full Text] [Related]
7. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
Park JA; Cheung NV
J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
[TBL] [Abstract][Full Text] [Related]
8. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity.
Choi HJ; Kim YJ; Lee S; Kim YS
Mol Cancer Ther; 2013 Dec; 12(12):2748-59. PubMed ID: 24132142
[TBL] [Abstract][Full Text] [Related]
9. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
[TBL] [Abstract][Full Text] [Related]
10. Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody.
Huang L; Xie K; Li H; Wang R; Xu X; Chen K; Gu H; Fang J
Drug Des Devel Ther; 2020; 14():3201-3214. PubMed ID: 32982167
[TBL] [Abstract][Full Text] [Related]
11. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies.
Shen J; Vil MD; Jimenez X; Zhang H; Iacolina M; Mangalampalli V; Balderes P; Ludwig DL; Zhu Z
J Immunol Methods; 2007 Jan; 318(1-2):65-74. PubMed ID: 17126853
[TBL] [Abstract][Full Text] [Related]
12. Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in
Xiong C; Mao Y; Wu T; Kang N; Zhao M; Di R; Li X; Ji X; Liu Y
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257416
[TBL] [Abstract][Full Text] [Related]
13. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.
Vitale LA; He LZ; Thomas LJ; Wasiuk A; O'Neill T; Widger J; Crocker A; Mills-Chen L; Forsberg E; Weidlick J; Patterson C; Hammond RA; Boyer J; Sisson C; Alvarado D; Goldstein J; Marsh HC; Keler T
Cancer Immunol Immunother; 2020 Oct; 69(10):2125-2137. PubMed ID: 32451681
[TBL] [Abstract][Full Text] [Related]
14. Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy.
Yuan Q; Liang Q; Sun Z; Yuan X; Hou W; Wang Y; Wang H; Yu M
Oncoimmunology; 2021; 10(1):1914954. PubMed ID: 34350059
[TBL] [Abstract][Full Text] [Related]
15. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
[TBL] [Abstract][Full Text] [Related]
16. Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities.
Li HY; Chen YL; Deng XN; Li HH; Tan J; Liu GJ; Zheng YJ; Pei M; Peng KT; Yue LL; Chen XJ; Liu Y; Zhao YS; Wang CH
Acta Pharmacol Sin; 2023 Nov; 44(11):2322-2330. PubMed ID: 37328649
[TBL] [Abstract][Full Text] [Related]
17. Bispecific Antibody Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells.
Jin J; Wang R; Yang J; Hu H; Wang D; Cai L; Fang Z; Dong S; Hu S; Wang Y; Liu B
Hum Gene Ther; 2022 Jun; 33(11-12):649-663. PubMed ID: 35272497
[TBL] [Abstract][Full Text] [Related]
18. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
[TBL] [Abstract][Full Text] [Related]
19. Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody.
Zheng S; Moores S; Jarantow S; Pardinas J; Chiu M; Zhou H; Wang W
MAbs; 2016; 8(3):551-61. PubMed ID: 26761634
[TBL] [Abstract][Full Text] [Related]
20. Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody.
Jarantow SW; Bushey BS; Pardinas JR; Boakye K; Lacy ER; Sanders R; Sepulveda MA; Moores SL; Chiu ML
J Biol Chem; 2015 Oct; 290(41):24689-704. PubMed ID: 26260789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]